Function of cell-cycle regulators in predicting silent pituitary adenoma progression following surgical resection

The present study investigated the use of cell-cycle regulators for predicting the progression of silent pituitary adenoma (SPA) following surgical resection, via immunohistochemical analysis of tumor samples obtained by surgical resection. The medical records of patients diagnosed with SPA between January 2000 and December 2013 in the Samsung Changwon Hospital, Sungkyunkwan University School of Medicine (Changwon, South Korea) were reviewed. Immunohistochemical staining was performed on sections of the archived, paraffin-embedded tissues obtained by surgery, with all tissues stained for cell-cycle regulatory proteins p16, p15, p21, cyclin-dependent kinase (CDK)4, CDK6, retinoblastoma protein (pRb) and cyclin D1, as well as E3 ubiquitin-protein ligase mib1 (MIB-1) antigen and p53. The primary end-point was to investigate the expression of cell-cycle regulatory proteins in SPA. The secondary end-point was to estimate the progression-free survival of patients with SPA following surgical resection and to identify its association with the expression of cell-cycle regulatory proteins. Of the 127 SPA samples, 44 (34.6%) were from patients with progression during a mean follow-up period of 62.4 months (range, 24.2–118.9 months). Immunohistochemical overexpression was identified in 61 samples (48.0%) for p16, 38 samples (29.9%) for p15, 19 samples (15.0%) for p21, 49 samples (38.6%) for CDK4, 17 samples (13.4%) for CDK6, 57 samples (44.9%) for pRb and in 65 samples (51.2%) for cyclin D1. Multivariate analysis revealed that null cell adenoma [95% confidence interval (CI), 0.276–0.808], somatotroph SPAs (95% CI, 1.296–3.121), corticotroph SPAs (95% CI, 1.811–4.078), pluripotent SPAs (95% CI, 2.264–5.194), decreased expression of p16 (95% CI, 2.724–5.588), overexpression of pRb (95% CI, 2.557–5.333), cyclin D1 (95% CI, 1.894–4.122) and MIB-1 (95% CI, 1.561–4.133), increased mitotic index (95% CI, 1.228–4.079), increased p53 expression (95% CI, 1.307–4.065) and invasion into the cavernous sinus (95% CI, 3.842–7.502) predicted SPA progression following resection. The results of the present study suggested that specific cell-cycle regulators, including p16, cyclin D1 and pRb, were associated with SPA progression.

[1]  K. Kovacs,et al.  Progress in the Diagnosis and Classification of Pituitary Adenomas , 2015, Front. Endocrinol..

[2]  Sarah E Mayson,et al.  Silent pituitary adenomas. , 2015, Endocrinology and metabolism clinics of North America.

[3]  P. Snyder,et al.  Silent (clinically nonfunctioning) pituitary adenomas , 2014, Journal of Neuro-Oncology.

[4]  Y. Lotan,et al.  Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma. , 2013, The Journal of urology.

[5]  B. Patel,et al.  Cyclin D1, retinoblastoma and p16 protein expression in carcinoma of the gallbladder. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[6]  Zhi Peng Su,et al.  Natural History of Postoperative Nonfunctioning Pituitary Adenomas: A Systematic Review and Meta-Analysis , 2012, Neuroendocrinology.

[7]  J. Koivukangas,et al.  Incidence of pituitary adenomas in Northern Finland in 1992-2007. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  Sun Wook Cho,et al.  Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas , 2010, Clinical endocrinology.

[9]  Alberto Fernández,et al.  Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.

[10]  G. Schackert,et al.  Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas , 2009, Genes, chromosomes & cancer.

[11]  岸本 一郎.  Abnormal expression of p16[INK4a], cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas , 2008 .

[12]  Xiao-yan Lin,et al.  Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53. , 2007, Archives of medical research.

[13]  S. Choi,et al.  Silent Adenomas of Pituitary Gland: It's Immunohistochemical Features and Clinical Characteristics. , 2006 .

[14]  John Eng,et al.  Receiver operating characteristic analysis: a primer. , 2005, Academic radiology.

[15]  K. Kovacs,et al.  Classification of pituitary adenomas , 2001, Journal of Neuro-Oncology.

[16]  B. Alberts,et al.  The Cell Cycle and Programmed Cell Death , 2002 .

[17]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[18]  F. Mangili,et al.  Proliferation Index of Nonfunctioning Pituitary Adenomas: Correlations with Clinical Characteristics and Long-term Follow-up Results , 2000, Neurosurgery.

[19]  T. Kokunai,et al.  Clinical features and growth fractions of pituitary adenomas. , 1997, Surgical neurology.

[20]  C. Matula,et al.  Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. , 1993, Neurosurgery.

[21]  E. Knosp,et al.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. , 1989, Neurosurgery.

[22]  B. Scheithauer,et al.  A novel type of pituitary adenoma: morphological features and clinical correlations. , 1988, The Journal of clinical endocrinology and metabolism.

[23]  P. Kleihues,et al.  Growth rate of human pituitary adenomas. , 1987, Journal of neurosurgery.

[24]  A. Klibanski.  Nonsecreting pituitary tumors. , 1987, Endocrinology and metabolism clinics of North America.

[25]  B. Scheithauer,et al.  Pathology of invasive pituitary tumors with special reference to functional classification. , 1986, Journal of neurosurgery.

[26]  E. Laws,et al.  Hormone-containing, non-secreting pituitary tumors: clinically silent monohormonal pituitary adenomas. , 1985, Transactions of the American Clinical and Climatological Association.

[27]  K. Kovacs,et al.  Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. , 1980, The American journal of pathology.